Drugs Made In America Acquisition II Corp. (DMII)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
DMII Chart
People also search for
Drugs Made In America Acquisition II Corp. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Daniel L. Lippincott Karpus Management Inc. | 2.6M | $25.9M | $26.19M | $285,771.79 | 1.1% |
| BO Brian Oliveira Clear Street Group Inc. | 181,521 | $1.8M | $1.83M | $32,673.67 | 1.82% |
| MCS Mercuria Capital Strategies LLC Mercuria Capital Strategies LLC | 750,000 | $7.48M | $7.56M | $82,500 | 1.1% |
| AAS ABC Arbitrage SA ABC Arbitrage SA | 40,000 | $396,000 | $403,200 | $7,200 | 1.82% |
 Mikhail Shilshtut Limestone Investment Advisors LP | 11,900 | $118,643 | $119,952 | $1,309 | 1.1% |
Drugs Made In America Acquisition II Corp. (DMII) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Drugs Made In America Acquisition II Corp. ever had a stock split?
Drugs Made In America Acquisition II Corp. Profile
| Trading Companies & Distributors Industry | Industrials Sector | Roger Bendelac CEO | NASDAQ (NMS) Exchange | G2851K104 CUSIP |
| US Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Drugs Made In America Acquisition II Corp. is a newly incorporated entity established in 2024 and located in Fort Lauderdale, Florida. As a blank check company, it currently does not engage in any significant operational activities. The primary objective of the company is to pursue strategic opportunities to merge, engage in share exchanges, acquire assets, or make share purchases with one or more businesses. This approach aims at reorganizing or recapitalizing ventures that align with the company's vision of enhancing the pharmaceutical industry landscape within the United States.
Products and Services
- Merger Opportunities:
The company aims to identify and collaborate with viable businesses in the pharmaceutical sector that may benefit from a merger. This process involves assessing synergies and the potential for operational growth in alignment with regulatory standards.
- Share Exchange Programs:
Drugs Made In America Acquisition II Corp. may engage with existing pharmaceutical companies to explore share exchange transactions. This service facilitates the sharing of equity among partnering entities, allowing for collaborative growth and market expansion.
- Asset Acquisitions:
By targeting specific assets in the pharmaceutical realm, the company will look to acquire properties that can enhance its portfolio and operational capacity. This strategy aims at increasing market competitiveness and value generation over time.
- Recapitalization Services:
Through strategic financial reorganizations, the company plans to assist businesses in restructuring their capital to optimize financial health. This approach is crucial for entities looking to stabilize or expand their operations effectively.
- Reorganization Consulting:
The company will provide consulting services to businesses seeking to improve their structural efficiency. By implementing reorganizational tactics, Drugs Made In America Acquisition II Corp. aims to help clients enhance productivity and market responsiveness.
